Monday, February 7, 2011

Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity


Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) – Growing need for second- and third-line therapies boosts commercial opportunity

Faced with limited growth opportunities in western markets, HIV drug developers are looking to expand into emerging markets, marked by a higher disease burden and greater medical unmet need. Efforts to improve treatment coverage coupled with a growing affluent middle class and private sector have turned countries like Brazil, Russia or India into a promising commercial opportunity.
Scope
  • Analysis of current HIV market dynamics across Brazil, Russia and India
  • Thorough assessment of underlying commercial and clinical factors, opportunities and threats shaping the antiretroviral market in these regions
  • Review of sales trends and brand dynamics of key branded and generic agents
  • Discussion of key domestic HIV drug makers as well as the position of major international players
Highlights
Brazil has one of most successful treatment programs for HIV-infected individuals, providing free access to HIV prevention and care. Despite challenges for international HIV drug makers arising from local competitors and compulsory licensing, growing concerns over drug resistance and intolerance are creating new revenue opportunities.
In Russia, HIV remained a low priority issue for several years but the situation has recently improved and the level of funding for treatment has increased. Given the lower level of generic incursion, there is significant opportunity for branded drugs due to the size of the epidemic, particularly as patients progress to late stage therapy.
Although the Indian HIV market is highly genericized, the introduction of the 2005 Patent Act could lead to improvements in intellectual property protection for global companies with branded products, illustrated by recent approvals for the patents of Selzentry, Isentress and Intelence in India.
Reasons to Purchase
*Identify key opportunities that will impact the use and uptake of new and existing HIV antiretrovirals
*Gain insight into the market environment for HIV antiretrovirals through a review of demographic, economic, regulatory and treatment trends
*Gain competitive advantage by identifying key HIV players, product characteristics and potential roles for new therapies
Buy Now : Market Research
Related Reports
at